glp-1 insurance premiums news Perspectives from employers on the costs and issues associated with covering agonists for weight loss Ro CEO talks new GLP-1
Description
The 5- and 10-year survival probabilities in this matched obesity cohort favored GLP-1 receptor agonist users, and the authors interpreted these data as suggesting a potentially meaningful long-term association between GLP-1 receptor agonist exposure and improved outcomes in this group
doi: 10.1186/s12933-024-02463-0
Pharmaceuticals ETF (NYSEMKT:IHE) offers concentrated exposure to domestic drugmakers, while iShares Global Healthcare ETF (NYSEMKT:IXJ) provides a broader, international footprint across the wider healthcare sector
Who May Not Be A Good Candidate For A GLP-1 Add-On
Intern Emerg Med 2023
